Retrovolution: HIV–Driven Evolution of Cellular Genes and Improvement of Anticancer Drug Activation

English version České info

In evolution strategies aimed at isolating molecules with new functions, screening for the desired phenotype is generally performed in vitro or in bacteria. When the final goal of the strategy is the modification of the human cell, the mutants selected with these preliminary screenings may fail to confer the desired phenotype, due to the complex networks that regulate gene expression in higher eukaryotes. We developed a system where, by mimicking successive infection cycles with HIV-1 derived vectors containing the gene target of the evolution in their genome, libraries of gene mutants are generated in the human cell, where they can be directly screened. As a proof of concept we created a library of mutants of the human deoxycytidine kinase (dCK) gene, involved in the activation of nucleoside analogues used in cancer treatment, with the aim of isolating a variant sensitizing cancer cells to the chemotherapy compound Gemcitabine, to be used in gene therapy for anti-cancer approaches or as a poorly immunogenic negative selection marker for cell transplantation approaches. We describe the isolation of a dCK mutant, G12, inducing a 300-fold sensitization to Gemcitabine in cells originally resistant to the prodrug (Messa 10K), an effect 60 times stronger than the one induced by the wt enzyme. The phenotype is observed in different tumour cell lines irrespective of the insertion site of the transgene and is due to a change in specificity of the mutated kinase in favour of the nucleoside analogue. The mutations characterizing G12 are distant from the active site of the enzyme and are unpredictable on a rational basis, fully validating the pragmatic approach followed. Besides the potential interest of the G12 dCK variant for therapeutic purposes, the methodology developed is of interest for a large panel of applications in biotechnology and basic research.

Vyšlo v časopise: Retrovolution: HIV–Driven Evolution of Cellular Genes and Improvement of Anticancer Drug Activation. PLoS Genet 8(8): e32767. doi:10.1371/journal.pgen.1002904
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1002904

Souhrn

Zdroje

1. ChristiansFC, ScapozzaL, CrameriA, FolkersG, StemmerWP (1999) Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Nat Biotechnol 17: 259–264.

2. ManskyLM (1998) Retrovirus mutation rates and their role in genetic variation. J Gen Virol 79: 1337–1345.

3. ManskyLM, TeminHM (1995) Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol 69: 5087–5094.

4. AbramME, FerrisAL, ShaoW, AlvordWG, HughesSH (2010) Nature, position, and frequency of mutations made in a single cycle of HIV-1 replication. J Virol 84: 9864–9878.

5. HuWS, TeminHM (1990) Retroviral recombination and reverse transcription. Science 250: 1227–1233.

6. Onafuwa-NugaA, TelesnitskyA (2009) The remarkable frequency of human immunodeficiency virus type 1 genetic recombination. Microbiol Mol Biol Rev 73: 451–480.

7. DasAT, ZhouX, VinkM, KlaverB, VerhoefK, et al. (2004) Viral evolution as a tool to improve the tetracycline-regulated gene expression system. J Biol Chem 279: 18776–18782.

8. DavisJN, van den PolAN (2010) Viral mutagenesis as a means for generating novel proteins. J Virol 84: 1625–1630.

9. WangL, JacksonWC, SteinbachPA, TsienRY (2004) Evolution of new nonantibody proteins via iterative somatic hypermutation. Proc Natl Acad Sci U S A 101: 16745–16749.

10. HuangP, ChubbS, HertelLW, GrindeyGB, PlunkettW (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110–6117.

11. Van RompayAR, JohanssonM, KarlssonA (2003) Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol Ther 100: 119–139.

12. HapkeDM, StegmannAP, MitchellBS (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 56: 2343–2347.

13. JordheimLP, GalmariniCM, DumontetC (2006) Gemcitabine resistance due to deoxycytidine kinase deficiency can be reverted by fruitfly deoxynucleoside kinase, DmdNK, in human uterine sarcoma cells. Cancer Chemother Pharmacol 58: 547–554.

14. TanakaM, JavleM, DongX, EngC, AbbruzzeseJL, et al. (2010) Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer 116: 5325–5335.

15. JordheimLP, DumontetC (2007) Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochim Biophys Acta 1776: 138–159.

16. WiewrodtR, AminK, KieferM, JovanovicVP, KapoorV, et al. (2003) Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing. Cancer Gene Ther 10: 353–364.

17. RainovNG (2000) A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 11: 2389–2401.

18. ManomeY, WenPY, DongY, TanakaT, MitchellBS, et al. (1996) Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 2: 567–573.

19. SabiniE, OrtS, MonnerjahnC, KonradM, LavieA (2003) Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol 10: 513–519.

20. McSorleyT, OrtS, HazraS, LavieA, KonradM (2008) Mimicking phosphorylation of Ser-74 on human deoxycytidine kinase selectively increases catalytic activity for dC and dC analogues. FEBS Lett 582: 720–724.

21. DrummondDA, SilbergJJ, MeyerMM, WilkeCO, ArnoldFH (2005) On the conservative nature of intragenic recombination. Proc Natl Acad Sci U S A 102: 5380–5385.

22. GalettoR, NegroniM (2005) Mechanistic features of recombination in HIV. AIDS Rev 7: 92–102.

23. KimT, MudryRAJr, RexrodeCA2nd, PathakVK (1996) Retroviral mutation rates and A-to-G hypermutations during different stages of retroviral replication. J Virol 70: 7594–7602.

24. FunamizuN, OkamotoA, KamataY, MisawaT, UwagawaT, et al. (2010) Is the resistance of gemcitabine for pancreatic cancer settled only by overexpression of deoxycytidine kinase? Oncol Rep 23: 471–475.

25. KroepJR, LovesWJ, van der WiltCL, AlvarezE, TalianidisI, et al. (2002) Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity. Mol Cancer Ther 1: 371–376.

26. HazraS, SzewczakA, OrtS, KonradM, LavieA (2011) Post-translational phosphorylation of serine 74 of human deoxycytidine kinase favors the enzyme adopting the open conformation making it competent for nucleoside binding and release. Biochemistry 50: 2870–2880.

27. Gutierrez-RivasM, Menendez-AriasL (2001) A mutation in the primer grip region of HIV-1 reverse transcriptase that confers reduced fidelity of DNA synthesis. Nucleic Acids Res 29: 4963–4972.

28. ManskyLM, Le RouzicE, BenichouS, GajaryLC (2003) Influence of reverse transcriptase variants, drugs, and Vpr on human immunodeficiency virus type 1 mutant frequencies. J Virol 77: 2071–2080.

29. BurtRK, DrobyskiWR, SereginaT, TraynorA, OyamaY, et al. (2003) Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. Exp Hematol 31: 903–910.

30. RiddellSR, ElliottM, LewinsohnDA, GilbertMJ, WilsonL, et al. (1996) T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med 2: 216–223.

31. SabiniE, HazraS, OrtS, KonradM, LavieA (2008) Structural basis for substrate promiscuity of dCK. J Mol Biol 378: 607–621.

32. GiverL, GershensonA, FreskgardPO, ArnoldFH (1998) Directed evolution of a thermostable esterase. Proc Natl Acad Sci U S A 95: 12809–12813.

33. PetrouniaIP, ArnoldFH (2000) Designed evolution of enzymatic properties. Curr Opin Biotechnol 11: 325–330.

34. ZuffereyR, NagyD, MandelRJ, NaldiniL, TronoD (1997) Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 15: 871–875.

35. NaldiniL, BlomerU, GallayP, OryD, MulliganR, et al. (1996) In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263–267.

36. YeeJK, MiyanoharaA, LaPorteP, BouicK, BurnsJC, et al. (1994) A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc Natl Acad Sci U S A 91: 9564–9568.

37. AgarwalKC, MiechRP, ParksREJr (1978) Guanylate kinases from human erythrocytes, hog brain, and rat liver. Methods Enzymol 51: 483–490.

38. SabiniE, HazraS, KonradM, LavieA (2007) Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem 50: 3004–3014.